Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
MRNA Price Action
Last 7 days
-7.7%
Last 30 days
-1.9%
Last 90 days
-16.9%
Trailing 12 Months
-78.1%
MRNA Stock Price
MRNA RSI Chart
MRNA Valuation
MRNA Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
MRNA Fundamentals
MRNA Revenue
MRNA Earnings
MRNA Profitability
MRNA Investor Care
MRNA Alerts
The Good News
Despite recent declines, Moderna (MRNA) experienced a massive growth surge during the pandemic, achieving over 2,300% increase in stock price and generating billions in earnings from its vaccine sales. Analysts still maintain a Hold rating, with some projecting a potential upside based on future innovations and product expansions.
The Bad News
Moderna's stock has plummeted 76.19% in the past year, and the company currently reports a troubling net profit margin of -110%. Analysts express caution, with a Sell rating from Leerink Partners and a low price target of $23.00, indicating a negative sentiment towards MRNA's immediate financial outlook.
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Product Sales
| |||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 0 |
| 2024 | 5.9B | 5.0B | 4.1B | 3.2B |
| 2023 | 15.1B | 10.7B | 9.1B | 6.8B |
| 2022 | 22.6B | 23.0B | 21.4B | 19.3B |
| 2021 | 2.7B | 7.0B | 11.8B | 18.5B |
| 2020 | 52.2M | 106.1M | 246.1M | 803.0M |
| 2019 | 122.1M | 106.3M | 81.6M | 60.2M |
| 2018 | 204.5M | 192.3M | 191.6M | 135.1M |
| 2017 | 132.8M | 157.1M | 181.5M | 205.8M |
| 2016 | 0 | 0 | 0 | 108.4M |
Get all data in R, Python etc through our Historical Stock Data APIs
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration agreement with CARsgen Therapeutics Holdings Limited to evaluate CTO41in combination with mRNA cancer vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| CEO | Mr. Stephane Bancel |
|---|---|
| WEBSITE | modernatx.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 3900 |
